Clinical Trials Browser

Withdrawn × Adenocarcinoma × pembrolizumab × Clear all

NCT02943603 2018-07-13

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms